Monoclonal antibodies raised against 167–180 aa sequence of human carbonic anhydrase XII inhibit its enzymatic activity

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90
   PubMed Web of Science ®Google Scholar
• Essaghir A, Demoulin JB. A minimal connected network of transcription factors regulated in human tumours and its application to the quest for universal cancer biomarkers. PLoS One 2012;7:e39666
   Web of Science ®Google Scholar
• Aktipis CA, Nesse RM. Evolutionary foundations for cancer biology. Evol Appl 2013;6:144–59
   PubMed Web of Science ®Google Scholar
• Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227–44
   PubMed Web of Science ®Google Scholar
• Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198–206
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 2005;338:617–26
   PubMed Web of Science ®Google Scholar
• Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266–76
   PubMed Web of Science ®Google Scholar
• Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007;19:223–9
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891–9
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007;15:4336–50
   PubMed Web of Science ®Google Scholar
• Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008;283:27799–809
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumour cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358–68
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006;42:167–216
   PubMed Web of Science ®Google Scholar
• Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394–9
   PubMed Web of Science ®Google Scholar
• Kallio H, Rodriguez Martinez A, Hilvo M, et al. Cancer-associated carbonic anhydrases ix and xii: effect of growth factors on gene expression in human cancer cell lines. J Cancer Mol 2010;5:73–8
   Google Scholar
• Ilie MI, Hofman V, Ortholan C, et al. Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer 2011;128:1614–23
   PubMed Web of Science ®Google Scholar
• Haapasalo J, Hilvo M, Nordfors K, et al. Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol 2008;10:131–8
   PubMed Web of Science ®Google Scholar
• Leppilampi M, Saarnio J, Karttunen TJ, et al. Carbonic anhydrase isozymes IX and XII in gastric tumours. World J Gastroenterol 2003;9:1398–403
   PubMed Web of Science ®Google Scholar
• Kim JY, Shin HJ, Kim TH, et al. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 2006;132:302–8
   PubMed Web of Science ®Google Scholar
• Chien MH, Ying TH, Hsieh YH, et al. Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol 2012;48:417–23
   PubMed Web of Science ®Google Scholar
• Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumours. J Med Chem 2011;54:8271–7
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012;3:84–97
   PubMed Web of Science ®Google Scholar
• Saleem M, Kamal M. Monoclonal antibodies in clinical diagnosis: a brief review application. Afr J Biotechnol 2008;7:923–5
   Google Scholar
• Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Canc Immun 2012;12:14–21
   PubMedGoogle Scholar
• Tostain J, Li G, Gentil-Perret A, Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer 2010;46:3141–8
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Matsumoto T, Ryuge S, et al. CAXII Is a sero-diagnostic marker for lung cancer. PLoS One 2012;7:e33952
   PubMed Web of Science ®Google Scholar
• Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother 2011;60:649–58
   PubMed Web of Science ®Google Scholar
• Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990;215:403–10
   PubMed Web of Science ®Google Scholar
• Jogaitė V, Zubrienė A, Michailovienė V, et al. Characterization of human carbonic anhydrase XII stability and inhibitor binding. Bioorg Med Chem 2013;21:1431–6
   PubMed Web of Science ®Google Scholar
• Dudutienė V, Zubrienė A, Smirnov A, et al. 4-Substituted-2,3,5,6-tetrafluorobenzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, XII, and XIII. Bioorg Med Chem 2013;21:2093–106
   PubMed Web of Science ®Google Scholar
• Dekaminaviciute D, Lasickiene R, Parkkila S, et al. Development and characterization of new monoclonal antibodies against human recombinant CA XII. Biomed Res Int 2013 [submitted]
   Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7
   PubMed Web of Science ®Google Scholar
• Zvirbliene A, Pleckaityte M, Lasickiene R, et al. Production and characterization of monoclonal antibodies against vaginolysin: mapping of a region critical for its cytolytic activity. Toxicon 2010;56:19–28
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumour-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A 2009;106:16233–8
   PubMed Web of Science ®Google Scholar
• Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005;24:487–99
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumour hypoxia: suppression of breast tumour growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76
   PubMed Web of Science ®Google Scholar
• Krishnamurthy VM, Kaufman GK, Urbach AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008;108:946–1051
   PubMed Web of Science ®Google Scholar
• Čapkauskaitė E, Zubrienė A, Baranauskienė L, et al. Design of [(2-pyrimidinylthio)acetyl]benzenesulfonamides as inhibitors of human carbonic anhydrases. Eur J Med Chem 2012;51:259–70
   PubMed Web of Science ®Google Scholar
• Ahlskog JK, Dumelin CE, Trüssel S, et al. In vivo targeting of tumour-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett 2009;19:4851–6
   PubMed Web of Science ®Google Scholar
• Loughrey BT, Williams ML, Healy PC, et al. Novel organometallic cationic ruthenium(II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase. J Biol Inorg Chem 2009;14:935–45
   PubMed Web of Science ®Google Scholar
• Morris JC, Chiche J, Grellier C, et al. Targeting hypoxic tumour cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem 2011;54:6905–18
   PubMed Web of Science ®Google Scholar
• Butowski N, Chang SM. Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control 2005;12:116–24
   PubMedGoogle Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714–27
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343–57
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody g250 recognizing carbonic anhydrase ix in renal cell carcinoma. Int J Mol Sci 2013;14:11402–23
   PubMed Web of Science ®Google Scholar
• Pastoreková S, Závadová Z, Kostál M, et al. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187:620–6
   PubMed Web of Science ®Google Scholar